Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD80 PE-Cy™5

Anti-Hu CD80 PE-Cy™5

Regulatory status

RUO

Antigen

CD80

Clone

MEM-233

Format

PE-Cy™5

Reactivity

Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

T8-287-T100

In stock

242.00 USD

25 tests

T8-287-T025

Delivery 1 week

121.00 USD

Variant

100 tests

T8-287-T100

In stock

242.00 USD

25 tests

T8-287-T025

Delivery 1 week

121.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The antibody MEM-233 reacts with an extracellular epitope of CD80 (B7-1), a 60 kDa single chain type I glycoprotein of immunoglobulin supergene family, expressed on professional antigen-presenting cells, such as dendritic cells, macrophages or activated B lymphocytes.

Workshop

HLDA IX

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Reactivity

Human

Immunogen

Extracellular domain of human CD80 fused to human IgG1(Fc)

Preparation

Purified antibody is conjugated with activated tandem dye of R-phycoerythrin-cyanine 5 (PE-Cy™5) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Cy™ and CyDye™ are registered trademarks of Cytiva.

Other names

B7-1, BB1

Antigen description

CD80 (B7-1) and CD86 (B7-2) are ligands of T cell critical costimulatory molecule CD28 and of an inhibitory receptor CTLA-4 (CD152). The both B7 molecules are expressed on professional antigen-presenting cells and are essential for T cell activation, the both molecules can also substitute for each other in this process. The question what are the differences in CD80 and CD86 competency has not been fully elucidated yet; there are still conflicts in results about their respective roles in initiation or sustaining of the T cell immune response.

Entrez Gene ID 941

UniProt ID P33681

Anti-Hu CD80 PE-Cy™5 antibody (clone MEM-233) specificity verification by flow cytometry

Anti-Hu CD80 PE-Cy™5 antibody (concentration in sample 3 μg/ml, red-filled histogram) binds specifically to CD80 on surface of CD80 transfected P815 cells (upper panel), but not to surface of non-transefected P815 cells (lower panel). Level of non-specific binding was assessed using Mouse IgG1 isotype control PE-Cy™5 antibody (MOPC-21) under same conditions (concentration in sample 3 μg/ml, black-dashed histogram).

General references:

Vasilevko V, Ghochikyan A, Holterman MJ, Agadjanyan MG: CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA. DNA Cell Biol. 2002 Mar;21(3):137-49.
PubMed

Yadav D, Judkowski V, Flodstrom-Tullberg M, Sterling L, Redmond WL, Sherman L, Sarvetnick N: B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets. J Immunol. 2004 Sep 15;173(6):3631-9.
PubMed

Product specific references:

Kolar GR, Mehta D, Pelayo R, Capra JD: A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood. 2007 Mar 15;109(6):2545-52.
PubMed

Lee DJ, Sieling PA, Ochoa MT, Krutzik SR, Guo B, Hernandez M, Rea TH, Cheng G, Colonna M, Modlin RL: LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol. 2007 Dec 15;179(12):8128-36.
PubMed

Campioni D, Moretti S, Ferrari L, Punturieri M, Castoldi GL, Lanza F: Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. Haematologica. 2006 Mar;91(3):364-8.
PubMed

Hovden AO, Karlsen M, Jonsson R, Aarstad HJ, Appel S: Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses. BMC Immunol. 2011 Jan 5;12:2.
PubMed

Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther. 2005 May;11(5):790-800.
PubMed

Derdak SV, Kueng HJ, Leb VM, Neunkirchner A, Schmetterer KG, Bielek E, Majdic O, Knapp W, Seed B, Pickl WF: Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13144-9.
PubMed

Silk KM, Leishman AJ, Nishimoto KP, Reddy A, Fairchild PJ: Rapamycin Conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. J. Biomed. Biotechnol., vol. 2012, article ID 172420, 11 pages, doi:10.1155/2012/172420

Zhan H, Towler HM, Calder VL: The immunomodulatory role of human conjunctival epithelial cells. Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3906-10.
PubMed

Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M: Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009 Jan;58(1):138-45.
PubMed